Astria Therapeutics, Inc.ATXSEarnings & Financial Report
Nasdaq
NextMar 31, 2026
ATXS Q3 2025 Key Financial Metrics
Revenue
$706.0K
Gross Profit
N/A
Operating Profit
$-34.1M
Net Profit
$-31.6M
Gross Margin
N/A
Operating Margin
-4830.6%
Net Margin
-4482.0%
YoY Growth
N/A
EPS
$-0.55
Financial Flow
Astria Therapeutics, Inc. Q3 2025 Financial Summary
Astria Therapeutics, Inc. reported revenue of $706.0K for Q3 2025, with a net profit of $-31.6M (-4482.0% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $706.0K |
|---|---|
| Net Profit | $-31.6M |
| Gross Margin | N/A |
| Operating Margin | -4830.6% |
| Report Period | Q3 2025 |
Income Statement
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Revenue | $0 | $706000 |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Assets | $361.6M | $271.9M |
| Liabilities | $20.0M | $38.6M |
| Equity | $341.7M | $233.3M |
Cash Flow
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Operating CF | $-28.0M | $-32.3M |